Lentigen is a diversified biologics company focused on the development and commercialization of breakthrough treatments for human disease. Lentiviral vectors (LV), the company's technology platform, are widely recognized by the scientific community as the most efficient method for delivery of genetic sequence information into cells to reprogram their function. The ability to efficiently and stably reprogram mammalian cells has numerous uses in biotechnology and biomedicine, including drug discovery, target validation, biologics manufacturing and cellular therapies.

Lentigen has established a strong intellectual property position in the area of LV technology. The combination of strong academic and corporate collaborations that support a robust proprietary pipeline are fueling company growth, while a diversity of funding models and business opportunities are mitigating risk.